USA Peter Marks, the US FDA’s top official for vaccines and cell and gene therapies, has resigned. A survivor of the first Trump administration, when his office faced intense pressure to fast-track COVID vaccine approvals, Marks reportedly clashed with new Health and Human Services Secretary Robert F. Kennedy Jr. and his…

Italy A roundup of some of the biggest pharma and healthcare stories coming out of Italy, including the country’s ever-falling birth rate; Chiesi’s new manufacturing investment; Doc Generici’s rebrand to DOC Pharma; Menarini’s oncology partnership with Insilico Medicine, and Angelini’s brain health deal with Cureverse.   Italian drug maker Recordati boosts…

Saudi Arabia Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact on health, societies, and economies is enormous. Moreover, over 90 percent of rare diseases have no known treatment, and rare disease patients often face delayed diagnoses and…

APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to Bayer, AbbVie accusing Genmab of ADC trade secret theft on ADC technology used by ProfoundBio, and Singapore’s A*STAR investing in…

Singapore Thanks to its strategic location and pro-business environment, Singapore has established itself as a major pharma manufacturing hub in the Asia-Pacific region. Five Big Pharma companies have stepped up their investments there as of late and either expanded existing manufacturing capabilities, or chosen the city-state as the location for a…

United Kingdom UK Prime Minister Keir Starmer’s government continues its push to overhaul the country’s iconic National Health Service (NHS). After originally announcing plans to restructure NHS England, the body that manages the NHS in England, it has now decided to eliminate it altogether. In a move that Starmer said would increase…

Spain A roundup of the biggest pharma news from Spain, including Grifols’ comeback after a turbulent 2024 when the company lost 30 percent of its market value; Almirall’s revenue and value surge; Rovi’s contract manufacturing downturn, and Lilly’s USD 50 million Madrid plant expansion.   Grifols expects to boost revenue and…

Denmark Zealand Pharma’s transformational journey from a niche biotech to a commercial-stage player in the booming global obesity market has reached another major milestone. As part of a USD 5.3 billion partnership with pharma giant Roche, Zealand will receive a USD 1.65 billion upfront payment, with Roche set to deliver Zealand’s…

Europe While Europe has lost some of its global share of clinical trials to China and the US, it remains a clinical research stronghold. Three years into the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to transform how trials are initiated, designed, and run across the…

MEA The latest pharma and healthcare news from the dynamic Middle East and Africa market, which reached USD 32.6 billion in value last year according to IQVIA. With supply security of essential medicines and vaccines still a hot-button issue, Egypt and Morocco are establishing a regional biomanufacturing hub for North Africa.…

Ireland In the latest chapter of the trade disputes launched by Donald Trump, the US president has accused Ireland of “stealing” pharma tax revenue. The country’s low corporate tax rates have attracted American heavyweights like Pfizer and Eli Lilly in recent years, but could changes to tax policy and trade tariffs…

China 2024 was another groundbreaking year for Chinese medicine approvals. Writing in the March 2025 edition of DIA’s Global Forum magazine, Juan Valencia S. and Angel Shao of PharmCube explain how and why.   Driven by drugmakers’ growing interest in accessing the world’s second-largest pharmaceutical market, China has recently seen a…